ArticleMultiple sclerosis journal - experimental, translational and clinical

Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany.

Dominik Koeditz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.